Achaogen is discovering and developing life-saving antibiotics.

Synosia Therapeutics is a CNS focused company developing novel treatments for psychiatric and neurological disorders.

Euro Ventures, Inc. is an incubator company forming development stage start ups through acquisition of assets from European-based pharma companies.

Sentient Pharmaceuticals is a seed stage start up company focused on developing products for outpatient interventional procedures.

Seredigm is focused on developing novel drugs that protect against tissue damage in a variety of acute or chronic medical conditions.

(NASDAQ:CADX)

Cadence Pharmaceuticals is developing and commercializing pharmaceuticals to meet the needs of hospitalized patients and their caregivers.

Kythera is focused on science and innovation in aesthetic dermatology.

(NASDAQ:ALXA)

Alexza is a specialty pharmaceutical company developing fast onset medications.

Amira is an R&D Company focused on the development of novel therapies for respiratory and other inflammatory diseases.

Amphora will create the first comprehensive chemical genomics knowledge set, detailing the interactions of small drug molecules with a broad array of protein targets. The company plans to commercialize this knowledge set in a series of drug discovery alliances with pharmaceutical and biotech companies and to sell drug candidates that Amphora has internally developed.

Antipodean is a drug development company focused on a platform of mitochondria targeted antioxidants for several degenerative diseases.

Delivery of simple, accessible bio-molecule detection and analysis solutions to the life sciences market.

5AM Ventures is a seed-stage fund focused on creating and building biotech companies.

FivePrime accelerates drug discovery by rapidly isolating and assaying the world's largest collection of pharmaceutically relevant targets and therapeutics from the human genome.

(NASDAQ:FLDM)

Fluidigm has developed the biological and chemical equivalent of the integrated circuit called Integrated Fluidic Circuits (IFC's). IFC's incorporate tens of thousands of miniature channels, pumps and valves. IFC's integrate biological and chemical reactions on a massive scale.

(NASDAQ:GHDX)

Genomic Health gives cancer patients and physicians insight needed to help make quality treatment decisions. The first diagnostic assay developed by Genomic Health – Oncotype DX™ – is a breast cancer test that may assist treatment planning by quantifying the likelihood of distant breast cancer recurrence.

(NASDAQ:HLCS)

Helicos BioSciences Corporation is developing instruments for high-speed sequencing of DNA or RNA without amplification.

Accelerator Corporation is building the next generation of life-enhancing biotechnology companies by providing world-class scientific and technical expertise, committed venture capital funding, state-of-the-art facilities and experienced biotechnology business management to accelerate the development of nascent leading-edge biotechnologies.

(NASDAQ:JAZZ)

Jazz Pharmaceuticals, founded by an executive team with outstanding experience and success in the pharmaceutical industry, will develop and market drugs serving the neurology and psychiatry markets.

Metabolex is an R&D based company focused on novel therapies for the treatment of diabetes and related metabolic disorders.

(NASDAQ:NOVC)

Novacea is an oncology biopharmaceutical company committed to creating a world-class drug development and commercialization organization that addresses significant unmet medical needs.

(Sold to Merck)

NovaCardia is an emerging cardiovascular pharmaceutical company focused on the development and commercialization of novel clinical stage drug candidates.

(Sold to Affymetrix)

ParAllele is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life sciences research, pharmaceutical, and diagnostic sectors.

(NASDAQ:PHRM)

Pharmion is an emerging pharmaceutical company focused on marketing drugs that require specialized medical education and marketing programs. Founded by two highly experienced industry executives, the company's initial focus is on drugs currently marketed for the treatment of cancer and related diseases for markets in the US, as well as in Europe and other major international markets.

Phenomix has developed a large-scale system for studying gene function in mice. Its strategy is unique in its ability to rapidly generate function for genes directly related to human disease, promising to lead to more rapid identification of new therapeutics.

Pathwork Diagnostics is developing innovative molecular diagnostic tests for cancer.

APT Pharmaceuticals is developing inhaled therapies for severe lung disorders.

OpGen is developing a molecular biology system to automate rapid (2-hour) identification of infection-causing bacteria for deployment in the central microbiology lab.

Trius Therapeutics, Inc. (formerly known as Rx3 Pharmaceuticals) is a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections.

Vital Therapies has developed the first human cell artificial liver, trade-named ELAD (Extracoporeal Liver Assist Device).

(Australian Stock Exchange:IPD)

Impedimed offers an innovative technology for monitoring lymphedema following breast cancer surgery.

Reliant Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, development and marketing of pharmaceutical products.

Saegis Pharmaceuticals is dedicated to developing new medicines that protect and improve memory and cognition.

(Sold to Cephalon)

Salmedix is focused on the development of clinical-stage drugs for the treatment of leukemias and lymphomas. The company has initiated human clinical trials for its first drug candidates, and is establishing a drug discovery to screen potential anticancer agents for a novel type of activity, which the company believes, will lead to a new strategy for fighting cancer.

(Sold to Takeda)

Syrrx is the technological leader in the field of structural proteomics. The company uses its proprietary technologies to generate protein structures, which are then used to rapidly discover new drugs.

CardioNow provides image management services for cardiology departments.

Cogent provides comprehensive hospitalist programs for acute care hospitals.

Collabrys provides outsourced, software-driven, full-service solutions that enable marketing professionals to launch new products, build brands, and increase consumer share.

Confirma sells CAD software tools for the management and analysis of breast MRI data.

RedBrick Health provides "Consumer Owned Healthcare Services" for large employers and their employees; manages cost for both employees and employers.

MedManage develops and deploys technology-based drug sampling solutions for pharmaceutical companies to accelerate prescription drug sales.

New Hope Bariatrics develops, markets, and operates centers of excellence for obesity surgery, providing outpatient surgery and related pre and post surgical care.

Skylight develops and operates hospital room interactive communication systems to provide hospital administrative and patient services.

Titan develops and operates ambulatory surgicenters.

Vantage develops and operates state-of-the-art radiation oncology centers.

Acclarent, Inc. offers a novel system for "balloon sinuplasty" to treat sinus disease.

AcuFocus is developing a corneal implant to treat presbyopia (the need for reading glasses).

Calypso Medical Technologies is a Seattle-based, early-stage medical device company developing a novel method of localizing tumors to better guide radiation therapy.

Cameron Health is developing a novel Implantable Cardioverting Defibrillator (S-ICD) without intravenous leads.

Cellutions is developing minimally invasive devices for cosmetic procedures.

Glaukos is developing an implantable device to treat glaucoma.

GluMetrics, Inc. is a medical device company f